AbbVie Files EMA Bid for Subcutaneous SKYRIZI in Crohn’s

AbbVie's regulatory move to seek European approval for a subcutaneous induction regimen of SKYRIZI (risankizumab) signals a broader manufacturing and formulation shift that biologics producers and QA leads should track closely. IV-to-subcutaneous reformulation strategies are drawing increasing scrutiny from EMA reviewers, and each submission in this space sets precedent for how agencies evaluate comparability, device integration, and sterility assurance in combination product dossiers.

The submission targets the induction phase of Crohn's disease treatment, where SKYRIZI is currently administered intravenously. Moving induction to a subcutaneous route requires demonstrating pharmacokinetic equivalence and container-closure integrity under a reformulated fill-finish process, obligations that sit squarely within ICH Q10 pharmaceutical quality system expectations and the comparability framework under ICH Q5E for biologics.

For contract manufacturers and in-house biologics facilities, the operational read is direct: subcutaneous reformulations demand validated primary packaging changes, revised extractables and leachables profiles, and device-drug combination assessments that can extend tech-transfer timelines by six to eighteen months depending on existing platform capability. Regulatory affairs leads preparing parallel submissions in other jurisdictions should note that EMA's Committee for Medicinal Products for Human Use typically requests bridging data packages that align with, but do not mirror, FDA expectations under 21 CFR Part 211 and associated biologics guidance.

The IV-to-subcutaneous trend is accelerating across the biologics sector, with multiple large-molecule sponsors pursuing route-of-administration line extensions to improve patient adherence and reduce infusion-center burden. Each approved reformulation adds to the body of precedent that agencies draw on when setting data expectations for the next submission, compressing the evidentiary bar in some areas while raising it in device reliability and human-factors validation.

AbbVie's EMA filing for subcutaneous SKYRIZI induction will serve as a reference point for how the agency weighs comparability packages in high-concentration monoclonal antibody reformulations targeting inflammatory bowel disease.

Source: Indian Pharma Post via Media4Growth, 27 August 2026.